Yutaka Midorikawa
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis 27
- Liver Disease and Transplantation 8
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 8
- Oncology top 5%
- Molecular Biology top 5%
- RNA modifications and cancer 8
- Epigenetics and DNA Methylation 8
- Epidemiology top 5%
- Liver Disease Diagnosis and Treatment 21
- Hepatitis B Virus Studies 8
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 17
- Co-authors
- Hiroyuki AburataniMasatoshi MakuuchiTadatoshi TakayamaShogo YamamotoTatsuhiko KodamaShingo TsujiShuichi TsutsumiShumpei Ishikawa
- Cited by
- HepatologyCancer ResearchOncology
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Yutaka Midorikawa
105 papers receiving 3.3k citations
Peers
Comparison fields: 5 of 129
- Hepatology 899
- Cancer Research 729
- Oncology 689
- Molecular Biology 1.7k
- Epidemiology 518
Countries citing papers authored by Yutaka Midorikawa
This map shows the geographic impact of Yutaka Midorikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yutaka Midorikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yutaka Midorikawa more than expected).
Fields of papers citing papers by Yutaka Midorikawa
This network shows the impact of papers produced by Yutaka Midorikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yutaka Midorikawa. The network helps show where Yutaka Midorikawa may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yutaka Midorikawa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 1 | |
| 3 | 2022 | 6 | |
| 4 | 2021 | 4 | |
| 5 | 2021 | 5 | |
| 6 | 2020 | 22 | |
| 7 | 2020 | 4 | |
| 8 | 2019 | 26 | |
| 9 | RISK OF SALMONELLA IN A SUBURBAN REGION OF VIENTIANE, LAO PEOPLE’S DEMOCRATIC REPUBLIC. | 2016 | 2 |
| 10 | 2016 | 8 | |
| 11 | 2013 | 102 | |
| 12 | 2011 | 101 | |
| 13 | 2010 | 1 | |
| 14 | 2010 | 83 | |
| 15 | 2009 | 191 | |
| 16 | 2008 | 70 | |
| 17 | 2008 | 46 | |
| 18 | Modeling and analysis of drug concentration-effect and time course patterns in gene expression data from microarray experiments. | 2005 | 3 |
| 19 | 2002 | 98 | |
| 20 | 1998 | 10 |
About Yutaka Midorikawa
Yutaka Midorikawa is a scholar working on Hepatology, Cancer Research and Endocrinology, having authored 110 papers that have together received 3.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (27 papers), Liver Disease Diagnosis and Treatment (21 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (17 papers), Cancer Genomics and Diagnostics (8 papers), RNA modifications and cancer (8 papers), Liver Disease and Transplantation (8 papers), Hepatitis B Virus Studies (8 papers) and Epigenetics and DNA Methylation (8 papers). The work is most often cited by research in Hepatology (899 citations), Cancer Research (729 citations) and Oncology (689 citations). Yutaka Midorikawa has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Hiroyuki Aburatani, Masatoshi Makuuchi, Tadatoshi Takayama, Shogo Yamamoto, Tatsuhiko Kodama, Shingo Tsuji, Shuichi Tsutsumi, Shumpei Ishikawa, Hirohiko Sakamoto and Masashi Fukayama. Their work appears in journals such as The EMBO Journal, PLoS ONE and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.